Arecor and GSK Form Collaboration to Advance New Vaccines

By Arecor, PRNE
Monday, June 13, 2011

CAMBRIDGE, England, June 14, 2011 -

Arecor and GSK have entered into a license agreement to develop
advanced formulations of vaccines combining Arecor’s unique
formulation technologies with GSK’s proprietary vaccines.  GSK
and Arecor have collaborated to develop new approaches which could
offer significant improvements to the administration of several
vaccines in development.  In return for the license to their
technology, Arecor will receive payments on relevant development
milestones and royalties on sales.

Tom Saylor, CEO of Arecor, stated, “Arecor is pleased to work
closely with one of the global leaders in vaccine products and
technology.  The relationship with GSK offers Arecor the
potential to apply its broad-ranging expertise in biomolecule
stabilisation to specific projects with GSK.”

Arecor Limited was established to provide formulation solutions
to pharmaceutical and biotech companies developing proteins,
vaccines and diagnostics based upon new insights into stabilization
of biologics.  Proteins and vaccines are often fragile
entities, and stability can represent significant constraints in
the development of new products and extending the use of existing
products.  Arecor has developed Arestat™, a patented set of
tools for stabilization which address the main pathways of
degradation.  As a simple reformulation, Arestat™ can be
readily incorporated into standard manufacturing practice, without
covalent modification of the biologic and using excipients approved
for the route of delivery. Arecor currently has active feasibility
programs and licenses with many of the top pharmaceutical and
biotech companies on a wide range of proteins and vaccines.


Tom Saylor, CEO href="">
Arecor Limited
2 Cambridge Science Park
Cambridge, UK


will not be displayed